OLX10212
Asset
- Stage
- Phase 2
- Modality
- Oligonucleotide
- Target
- Not known
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Geographic atrophy
Phase 2, hitnews.co.kr, 12 Oct 2026
Macular degeneration
Phase 2, hitnews.co.kr, 13 Oct 2026
In the full profile
- Owner and partners1
- Competitors2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.